Novel agents for castration-resistant prostate cancer: Early experience and beyond.

about

Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.

P2860

Q38803264-F3B1658F-C208-422D-A036-C1528580D2DE Q38865487-9BAEAD86-62A4-44B3-BD5D-AF9E46AB90C4

P2860

Novel agents for castration-resistant prostate cancer: Early experience and beyond.

Item

http://www.wikidata.org/entity/Q38574684

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Novel agents for castration-resistant prostate cancer: Early experience and beyond.

@en

type

Item

label

Novel agents for castration-resistant prostate cancer: Early experience and beyond.

@en

prefLabel

Novel agents for castration-resistant prostate cancer: Early experience and beyond.

@en

P1476

Novel agents for castration-resistant prostate cancer: Early experience and beyond.

@en

P2093

Naohiro Fujimoto

http://www.w3.org/2001/XMLSchema#string

P2860

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

P304

114-121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJU.12907

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281341933

http://www.w3.org/2001/XMLSchema#string

P698

26311471

http://www.w3.org/2001/XMLSchema#string

Novel agents for castration-resistant prostate cancer: Early experience and beyond.

about

P2860

P2860

Novel agents for castration-resistant prostate cancer: Early experience and beyond.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698